DexCom (DXCM) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates

The upcoming report from DexCom (DXCM) is expected to reveal quarterly earnings of $0.45 per share, indicating an increase of 4.7% compared to the year-ago period. Analysts forecast revenues of $1.12 billion, representing an increase of 11.8% year over year.

Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.

Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.

While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.

In light of this perspective, let's dive into the average estimates of certain DexCom metrics that are commonly tracked and forecasted by Wall Street analysts.

Analysts forecast 'Revenue- Hardware' to reach $38.99 million. The estimate indicates a year-over-year change of -32%.

It is projected by analysts that the 'Revenue- Sensor and other' will reach $1.08 billion. The estimate suggests a change of +14.5% year over year.

According to the collective judgment of analysts, 'Revenue- United States' should come in at $809.70 million. The estimate indicates a change of +10.6% from the prior-year quarter.

The combined assessment of analysts suggests that 'Revenue- International' will likely reach $311.29 million. The estimate indicates a year-over-year change of +14.3%.

View all Key Company Metrics for DexCom here>>>

Over the past month, DexCom shares have recorded returns of +3.1% versus the Zacks S&P 500 composite's +4.9% change. Based on its Zacks Rank #2 (Buy), DXCM will likely outperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

5 Stocks Set to Double

Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include

Stock #1: A Disruptive Force with Notable Growth and Resilience

Stock #2: Bullish Signs Signaling to Buy the Dip

Stock #3: One of the Most Compelling Investments in the Market

Stock #4: Leader In a Red-Hot Industry Poised for Growth

Stock #5: Modern Omni-Channel Platform Coiled to Spring

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.

Download Atomic Opportunity: Nuclear Energy's Comeback free today.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

DexCom, Inc. (DXCM) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.